Author

Gary W. Ashley

ProLynx (United States)ORCID 0000-0002-5366-9109Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Daniel V. SantiiD· 1 shared Eric L. SchneideriD· 1 shared John A. HangaskyiD· 1 shared Rocío del Valle FernándeziD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

4 top collaborators · 6 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Daniel V. SantiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The limitation of lipidation: conversion of semaglutide from once-weekly to once-monthly dosing

Eric L. Schneider, John A. Hangasky, Rocío del Valle Fernández, Gary W. Ashley, Daniel V. Santi

This study develops a once-monthly dosing form of semaglutide using hydrogel microspheres, showing equivalent weight loss to daily dosing in mice and simulating human efficacy.

Proceedings of the National Academy of Sciences · Nov 12, 2024Peer-reviewedBioengineering